[Lamotrigine in the therapy of resistant epilepsy].

Objective: To evaluate the efficacy of lamotrigine as single agent in patients with refractory epilepsy.

Materials And Methods: Forty-seven adult patients with refractory epilepsy, in the initial phase received carbamazepine (1208 +/- 82.9 mg/day) plus lamotrigine (561.

[Efficacy of vigabatrin associated with carbamazepine in the treatment of epilepsy. Follow up 1993-1996].

Purpose: To verify tolerance and clinical efficacy of vigabatrin (VGB), a new antiepileptic drug, in an add-on therapy with carbamazepine (CBZ).

Patients And Methods: From september 1993 to december 1996, 35 patients with partial complex seizures (CPC) and CPC plus secondary generalization were treated, with VGB plus CBZ, VGB dose was 1.41 +/- 0.

[Lamotrigine: monotherapy in refractory epilepsy].

CBZ (mean 1219 mg, DS +/- 94.6) + LTG (mean 55.8 mg, DS +/- 80) were administered in 31 subjects with refractory partial complex and/or partial secondary generalized seizures.

[Felbamate: a long-term study in subjects with refractory epilepsy].

Unlabelled: 18 patients with refractory complex partial seizures with or without secondary generalization resistant at common AED were studied. They were treated in a open label study with felbamate for a 22 months period. Felbamate monotherapy show a statistical significant improvement in the control of seizures in these patients versus CBZ therapy.

[New antiepileptic drugs: a review and personal contribution].

In drug-resistant epilepsy the use of VGB, LTG, oxcarbazepine, FBM and GBP resulted in at least a 50% improvement in 20% to 60% of such patients treated and in 7% led to complete seizure control. In the long term, VGB may lose its efficacy and give rise to tolerance phenomena. Another frequent disadvantage of VGB is poor compliance owing to the large number of tablets needed to achieve the necessary dose (2-3 g).